Friedreich’s ataxia Pipeline Analysis report covers 23 drugs currently in different phases of development. Friedreich’s ataxia (FA or FRDA) is a rare genetic disorder which causes degeneration of the nervous system leading to the coordination and movement problems. The disorder worsens with time where the spinal cord and peripheral nerves become thinner resulting into unsteady movements and impaired sensory functions. It is caused by the mutation of FXN gene and can be inherited by both male and female. However, it does not affect the cognitive abilities of an individual.
The report provides Friedreich’s ataxia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Reata Pharmaceuticals, Inc., AbbVie Inc., Shire and Cardero Therapeutics Inc. among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration